Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Multiple Myeloma
Multiple Myeloma
IKEMA Study: Isatuximab plus Carfilzomib and Dexamethasone in Patients with RRMM
Multiple Myeloma
In Patients with RRMM, Idecabtagene Vicleucel, a BCMA-Directed CAR T-Cell Therapy: CRB-401 Study Updates
Multiple Myeloma
CARTITUDE-1: In Patients with RRMM, Ciltacabtagene Autoleucel, a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy
Multiple Myeloma
In Patients with RRMM Teclistamab, a BCMA × CD3 Bispecific Antibody: Phase 1 Study Updates
Multiple Myeloma
In Patients with RRMM, REGN5458, a BCMA × CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses
Multiple Myeloma
APOLLO: In Patients with RRMM, Daratumumab plus Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone
Multiple Myeloma
Ixazomib, Daratumumab, and Low-Dose Dexamethasone Induction in Frail, Elderly Patients with NDMM
Multiple Myeloma
CANDOR Study: Subgroup Analysis of Carfilzomib and Dexamethasone with or without Daratumumab in RRMM
Multiple Myeloma
Belantamab Mafodotin Combined with Pomalidomide and Dexamethasone for RRMM: A Dose-Finding Study
Multiple Myeloma
DREAMM-2 Study Evaluated Belantamab Mafodotin in Patients with RRMM: Prior Therapy Analysis
1
2
3
4
Page 1 of 4
Results 1 - 10 of 31